Corona Remedies Limited reports FY26 revenue growth of 17.3%

Corona Remedies Limited reported FY26 revenue of ₹1,403.2 crore, a year-on-year increase of 17.3%, while its India business grew 17.18% against 8.59% growth in the Indian Pharmaceutical Market. The performance shows that Corona Remedies expanded at more than twice the market rate during the year ended March 31, 2026.

How did Corona Remedies perform in FY26?

Corona Remedies delivered 17.3% year-on-year revenue growth in FY26, with revenue reaching ₹1,403.2 crore. The company reported EBITDA of ₹293.4 crore, up 22.3%, and adjusted profit after tax of ₹199.4 crore, up 33.4%, according to its May 2026 investor presentation.

The EBITDA margin for FY26 stood at 20.9%, improving by 85 basis points year-on-year. Adjusted PAT margin was 14.2%, an expansion of 172 basis points. Higher growth in profit than revenue indicates that margins improved during the year, based on the financial metrics disclosed by the company.

Corona Remedies reported a 20.2% increase in fourth-quarter revenue to ₹353.1 crore. Q4 EBITDA was ₹62.0 crore, up 14.4%, while adjusted PAT rose 43.7% to ₹45.3 crore. The Q4 EBITDA margin was 17.6%, down 89 basis points, whereas PAT margin increased 210 basis points to 12.8%.

The Board of Directors presented these results with the company’s 22nd Annual Report and audited financial statements for the year ended March 31, 2026. The annual report described FY26 as a landmark year for the India business.

Why did Corona Remedies outpace the Indian Pharmaceutical Market?

Corona Remedies outpaced the Indian Pharmaceutical Market because its India business grew 17.18%, compared with IPM growth of 8.59% in PharmaTrac MAT March 2026 data. This represents an outperformance of 859 basis points, according to the company’s director report.

The company is an India-focused branded pharmaceutical formulation business. Its stated therapeutic focus includes women’s healthcare, cardio-diabeto, pain management and urology, along with other therapeutic areas. The director report said India contributed 96% of the company’s business, making domestic prescription demand and execution in the Indian market central to its financial performance.

Corona Remedies attributed its growth in investor presentations to brand strength and its distribution network. During Q3 FY26 and the first nine months of FY26, it said chronic therapies contributed 71.6% of total revenue. That disclosed mix provides context for the company’s focus on therapy areas that typically require continuing treatment.

The difference between the 17.18% India-business figure in the annual report and the 17.3% FY26 revenue growth in the investor presentation is consistent with rounded reporting and the use of separate operating measures. Both figures indicate growth above the reported IPM rate.

What were the main operational developments during the year?

Corona Remedies continued to build its manufacturing and market-access capabilities during FY26. Its Bhayla facility received EAEU-GMP certification in January 2026, according to the February 2026 investor presentation.

The certification enables entry into five Eurasian Economic Union markets: Russia, Kyrgyzstan, Armenia, Belarus and Kazakhstan. Corona Remedies stated that these markets represent an opportunity of up to about US$25 billion. The disclosure identifies a regulatory route for international market access, though the company did not provide sales guidance or revenue projections for these markets.

The company’s operations remain primarily domestic, given the 96% contribution from India business stated in the director report. Therefore, the EAEU-GMP development should be viewed alongside the scale of the domestic franchise rather than as evidence of a near-term change in the company’s revenue mix.

Corona Remedies also disclosed Q1 FY27 results in its July 2026 investor presentation. Revenue for the quarter ended June 30, 2026 was ₹422.4 crore, up 21.9% year-on-year. EBITDA rose 33.5% to ₹93.1 crore, with a 22.0% margin, and PAT increased 30.1% to ₹60.1 crore, with a 14.2% margin.

How does the performance matter for investors and the pharma sector?

Corona Remedies’ FY26 performance matters because it combined revenue growth above the IPM rate with higher EBITDA and adjusted PAT growth. Revenue expanded 17.3%, while EBITDA and adjusted PAT increased 22.3% and 33.4%, respectively, indicating improved reported profitability for the year.

For investors, the key disclosed indicators are the company’s domestic concentration, margin movement and therapeutic exposure. India accounted for 96% of business, while chronic therapies formed 71.6% of revenue during Q3 and 9M FY26. These figures underline the importance of prescription demand, brand performance and distribution in the domestic pharmaceutical market.

No share-price movement or valuation data was included in the supplied disclosures. Corona Remedies listed on the BSE and NSE on December 15, 2025, following an initial public offering of ₹655.37 crore. The IPO price band was ₹1,008 to ₹1,062 per equity share, with a minimum application size of 14 shares.

The company offered eligible employees a discount of ₹54 per share in the employee reservation portion. The IPO was structured as an offer for sale, based on the supplied offer description. The disclosures provided do not state how the FY26 operating performance affected trading in the shares.

What should investors monitor after the FY26 results?

Investors should monitor whether Corona Remedies sustains revenue growth above the IPM and maintains its reported margin profile. The company’s Q1 FY27 figures showed 21.9% revenue growth and a 22.0% EBITDA margin, extending the growth trend disclosed for FY26.

Execution in chronic therapies, where the company reported a 71.6% revenue contribution in Q3 and 9M FY26, remains relevant to its India-focused business. Progress following EAEU-GMP certification at the Bhayla facility is also a disclosed operational item to track, particularly any future update on commercial activity in the five eligible Eurasian markets.

The FY26 financial results also establish a comparison base for subsequent quarters. Revenue was ₹1,403.2 crore, EBITDA margin was 20.9%, and adjusted PAT margin was 14.2%. Future disclosures can be assessed against these reported FY26 levels and the 8.59% IPM growth benchmark cited by the company.

Conclusion

Corona Remedies reported a stronger FY26 than the Indian Pharmaceutical Market benchmark cited in its director report. The company’s revenue rose 17.3% to ₹1,403.2 crore, while EBITDA and adjusted PAT grew faster than revenue and margins improved for the full year.

The next disclosed reference point is the company’s quarterly performance after Q1 FY27, when it reported revenue growth of 21.9%. Investors will also watch for updates on domestic growth relative to the IPM and the company’s plans following Bhayla’s EAEU-GMP certification.